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ABSTRACT 
 
GEORGE I. GETZ: NSDHL Mutations Associated with CHILD Syndrome Identified in  
Oral Verruciform Xanthoma 
(Under the direction of Jonathan Reside) 
 
While the etiology of Verruciform xanthoma (VX) lesions remains unclear, recent 
evidence suggests the possible role of a mutation in the NAD(P)-dependent steroid 
dehydrogenase-like (NSDHL) gene in cutaneous lesions.  The aim of this study is to evaluate 
the presence of mutations of the NSDHL gene in cases of oral VX. 
A total of 112 oral VX lesions were diagnosed at the UNC Pathology Laboratory and 
Biopsy Service between 2005-2017.  DNA was extracted from the archived formalin-fixed 
and paraffin tissue blocks in a subset of 20 patients.  Polymerase chain reaction was then 
used to screen for the presence of four known germline mutations in the NSDHL gene 
associated with congenital hemidysplasia with ichthyosiform nevus and limb defects 
(CHILD) Syndrome and one somatic mutation that was identified in VX lesions in a previous 
study with no known CHILD syndrome association. 
A total of eight of the tissue samples had known missense mutations associated with 
CHILD syndrome.  Furthermore, two of these aforementioned eight tissue samples also had 
additional missense mutations previously identified in VX lesions.  Thus, oral VX lesions 
may be associated with mutations in the NSDHL gene.
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CHAPTER 1: 
INTRODUCTION
 
VERRUCIFORM XANTHOMA 
VX primarily affects the oral mucosa.  First described by Shafer in 1971, it most 
commonly presents with a well-circumscribed verrucous or papillomatous appearance, 
however, in some instances VX may appear flat, polypoid or sessile (Shafer, 1971) (Figure 
1).  It usually occurs as a small (2mm–2cm), solitary, asymptomatic, slow growing, white, 
pink, grey, or yellowish lesion (Neville, 1986).  Oral VX lesions are most commonly found 
on the gingiva (40.9-70.6%) (Philipsen et al., 2003), as well as the mandibular ridge, palate, 
floor of the mouth, lip, and mucobuccal fold (Shafer, 1971).  Lesions have also been 
identified on the faucial pillars and the upper respiratory tract (Sathish et al., 2013; Travis et 
al., 1989). The differential diagnosis for oral VX includes squamous papilloma, verruca 
vulgaris, condyloma acuminatum, verrucous leukoplakia, squamous cell carcinoma, and 
gingival epulis (Qi et al., 2014). Histological evaluation following excisional biopsy is the 
primary means of diagnosis. Treatment via excision is usually curative for oral VX lesions as 
recurrence is rare (Shetty et al., 2013); only three recurrent cases have ever been described, 
and all were localized to the hard palate (Nowparast et al., 1981).  In cutaneous VX, 
however, persistent recurrence is reported, although the condition eventually resolves 
(Connolly et al., 2003). No malignant transformation of VX has ever been reported, although 
two cases of oral VX were observed in association with carcinoma in situ and squamous cell 
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carcinoma, likely due to the degenerative epithelial changes in these oral lesions (Neville et 
al., 1986). 
While the majority of oral VX lesions are isolated and solitary, multifocal lesions 
have been described in association with several diseases and conditions, including chronic 
graft-versus-host disease.  However, multifocal lesions may also occur in otherwise healthy 
patients; four solitary gingival VX lesions were once identified in a patient with no systemic 
disease (Qi et al., 2014). 
Extraoral VX lesions were first identified and described by Santa Cruz and Martin in 
1979. Extraoral lesions are most commonly found involving the anogenital mucosa and 
epidermis, although lesions have also been identified on the penis and scrotum (Santa Cruz et 
al., 1979, Philipsen et al., 2003).  In 2013, a 8mm diameter solitary VX lesion was found on 
the forearm of an 82-year-old male with an unremarkable medical history and no history of 
trauma to the area (Blankenship et al., 2013).  Multiple extraoral VX lesions are usually 
associated with conditions such as epidermal nevi, lymphedema, and CHILD syndrome 
(Neville, 1986). 
No data is available concerning the prevalence or incidence of oral VX.  During the 
course of a 12-year period, 6 VX lesions were diagnosed from a total of 24,245 specimens in 
a university oral pathology laboratory setting, for a frequency of 0.025% (Buchner et al., 
1981).  In a 2002 literature review of 282 cases, oral VX occurred in females (mean age, 54.9 
years) and males (mean age, 44.2 years) in a 1:1.1 female:male ratio.  109 out of the 282 
cases were from Japanese patients, but a comparison with non-Japanese patients showed few 
discrepancies (Philipsen et al., 2003). 
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Histologically, in oral VX, the epithelium has a pebbly or verruciform surface, 
although it occasionally may appear flat (Nowparast et al., 1981).   There is invagination of 
hyperkeratosis into crypts in the stratified squamous epithelium (Huang et al., 1986).  
Hematoxylin and eosin (H&E) staining of this parakeratin will produce a characteristic 
orange color, clearly separating the epithelium  associated with the lesion from the 
surrounding epithelium.  Often the parakeratinized surface will appear rough and will display 
infiltrations of neutrophils.  Uniform elongation of rete pegs is characteristically present.  
However, the hallmark of VX is the presence of foamy (lipid-laden) cells, or xanthoma cells, 
within the connective tissue papillae between the rete ridges (Figure 2).  These xanthoma 
cells do not usually extend deeper into the connective tissue than the tips of the rete pegs 
(Neville, 1980).  Isolated foamy cells have also been noted within the epithelium in some 
cases (Cobb et al., 1976).  Histologically, differentiation from other lesions that have foamy 
cells is not difficult as VX is the only lesion known to have these type cells confined to the 
connective tissue papillae (Shetty et al., 2013).  Although there was some disagreement about 
the origin of the foam cells in the past, immunohistochemistry suggests that foam cells 
descend from macrophages, as they are positive for CD-68 and cathepsin B antibodies 
(Mostafa et al.,1993; Oliveira et al., 2001).  Scattered lymphocytes and plasma cells may also 
be present in the connective tissue.  Additional staining with Scharlach R stain has 
demonstrated the presence of lipid granules within the xanthoma cells and the overlying 
epithelium (Zegarelli et al., 1975).  Periodic acid-Schiff positive, diastase-resistant granules 
have been found in the cytoplasm of the xanthoma cells (Shafer et al., 1971; Zegarelli et al., 
1975; Santa Cruz et al., 1971).  Occasionally, fungal hyphae or bacterial infiltrate may also 
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be identified (Mostafa et al., 1993), but it is thought that presence of these microbes most 
likely represents a secondary infection (Neville, 1980). 
Electron microscopy of gingival oral VX lesions revealed the presence of lipid-laden 
macrophages (Zegarelli et al., 1975).  A typical macrophage had an irregular nuclear profile 
with prominent nucleolus and the cytoplasm containing numerous large lipid vacuoles.  
Epithelial cell degeneration was evident with VX.  Lipid containing vacuoles were identified 
in epithelial cells as well in the intercellular spaces between epithelial cells (Zegarelli et al., 
1975).  Light microscopy of cutaneous VX from the penis displayed numerous lipid vacuoles 
in melanocytes as well.  Some of these were seen to be within the disrupted basal layer of the 
epithelium where they could reach the foam cells in the dermis (Balus et al., 1991). 
There are a several theories on the etiology and pathogenesis of VX.  Early on, noting 
that VX commonly occurs at areas of masticatory mucosa, it was proposed that epithelial 
degradation initiates formation of the characteristic foam cells (Zegarelli et al., 1975). The 
epithelium becomes entrapped with the crypts within the stratified squamous epithelium and 
is not lost from the body.  The entrapped epithelium then degenerates, eventually forming 
lipids.  The products of this breakdown elicit an inflammatory response, explaining the 
neutrophil infiltrate that is often seen within the epithelium and a mostly chronic cell 
infiltrate in the submucosa (Zegarelli et al., 1975).  It is unclear, however, how the initial 
crypt that would necessitate the entrapment of epithelial cells form, although it is proposed it 
may be caused by a local irritant (Mehra et al., 2005).  Later studies, however, observed foam 
cell deposition in areas of little epithelial degradation and without entrapment of epithelial 
cells (Travis et al., 1989).  In a study of a multifocal VX in the upper aerodigestive tract of a 
child, three morphological manifestations of VX (verruciform, papillary, and flat) were 
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identified within the same individual. This suggested that the squamous epithelium 
progresses through flat and papillary stages, before becoming verrucous.  Citing that 
macrophages are known to produce a variety of growth factors (Nathan, 1987), it was 
suggested that the foam cells might play a role in inducing epithelial hyperplasia.  Therefore, 
it is believed that the accumulation of foam cells is the primary abnormality in the early 
lesion and that increasing epithelial hyperplasia and inflammation are secondary 
manifestations (Travis et al., 1989). 
In order to discover the local factors that may regulate the recruitment and 
accumulation of the xanthoma cells in the connective tissue papilla, the cellular and 
molecular pathways of chronic inflammation have been studied using immunohistochemical 
techniques.  It was suggested that keratinocyte hyperplasia may be initiated and maintained 
by T cell-mediated inflammation as a response to altered keratinocytes.  Furthermore, they 
discovered MCP-1 localized in the basal layer of VX and CCR2 expressed in its foam cells. 
MCP-1 is a potent macrophage attractor and CCR2 up-regulates macrophage and T-cell 
trafficking.  They suggested that this MCP-1/CCR2 axis may serve to induce macrophages in 
the sub-basal layer (Ide et al., 2008).  This may explain why oral VX is most commonly 
identified on gingiva tissues, as gingivitis and chronic periodontitis are examples of T cell 
activation and keratinocyte expression of MCP-1.  In fact, P. gingivalis can up-regulate the 
secretion of MCP-1 (Kuramitsu et al., 2002).  
Lending further credence that VX may be the result of a chronic inflammatory 
process, Rawal et al., 2007, in the first study of its kind, characterized the phenotypes of the 
foam cells in VX at different oral locations.  They found that the resident and chronic 
inflammatory reparative macrophage subtypes far outnumbered the acute inflammatory foam 
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cells, consistent with a chronic reactive process.  This was found consistently, regardless of 
the location of the VX lesions. 
The source of the lipid contained in foam cells has been the subject of investigation, 
in the hope that this may lead to the identifying the pathophysiology of VX.  It has been 
suggested by some (Huguet et al., 1995; Kishimoto et al., 1998; Wu et al., 2003) that it may 
derive from serum lipoprotein.  However, squamous epithelium are active sites of lipid 
biosynthesis (Ide et al., 1998), these lipids increase in conditions of chronic inflammatory 
dermatoses (Uchiyama et al., 2000), and the ultrastructure of VX reveals membrane-bound 
lipid-laden vacuoles and foamy macrophages within the epithelium (Zegarelli et al., 1975).  
Therefore, it appears that the theory that the degradation of the epithelium, and the resultant 
uptake of the keratocyte’s lipids by macrophages in the dermis, may, in fact, lead to the 
formation of the pathognomonic foam cells of VX (Balus et al., 1991). 
As the clinical manifestation is often verruciform or papillary, and common locations 
for VX are the oral cavity or genitalia, a viral etiology, and specifically Human Papilloma 
Virus (HPV), has been suggested (Mehra et al., 2005).  However, multiple studies have failed 
to prove such a connection.  While HPV DNA has been found in condyloma-appearing VX 
(Hu et al., 2005) and one case report found an association between HPV type 6a particles 
found in the nucleus of keratinocytes of a cutaneous VX (scrotum) lesion after PCR and 
sequence analysis (Khaskhely et al., 2000), no signs of HPV infection have ever been 
detected.   
There are several other diseases and syndromes that have shown an association with 
VX.  There is one case study where an association was found with both a rare type of 
congenital lymphedema, chronic hereditary lymphedema (“Milroy Disease”), and leaky 
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capillary syndrome, a condition where vascular permeability leads to hemodynamic disorder.  
The locations of the multifocal papillary lesions in both cases were in the lower extremities. 
It was reasoned that accumulation of lipids in subcutaneous tissues gave rise to the 
characteristic foamy cells in their patient’s VX, the result of atypical peripheral lymphatics 
and permeable capillaries, allowing exudation into subcutaneous tissue.  Indeed, Hunter et al. 
proposed this mechanism for VX in 1970 (Wu et al., 2003). 
More recently, VX has been associated with CHILD syndrome, a rare x-linked 
autosomal dominant disorder caused by a mutation of the NAD[P]H steroid dehydrogenase-
like (NSHDL) gene involved in cholesterol biosynthesis (Mehra et al., 2005).  The lesions in 
CHILD syndrome and VX have a similar morphological and histological appearance, 
including the appearance of foam cells confined to the connective tissue papillae.  The 
authors surmised that this inactivation of the NSDHL gene also plays a role in sporadic VX. 
 
NAD[P]H STEROID DEHYDROGENASE-LIKE (NSHDL) GENE 
Cholesterol is a major precursor of steroid hormones, influencing embryonic and 
postnatal development.  The NSHDL gene encodes for a 3b-hydroxysteroid dehydrogenase 
located within the membranes of endoplasmic reticulum and on the surface of intracellular 
lipid storage droplets that is involved in one the later steps of the biosynthesis pathway of 
cholesterol, where C-4 methyl groups are removed (Caldas et al., 2003; Preiksaitene et al., 
2015).  Its chromosomal location is on the long arm of the X chromosome at position 28 
(Xq28).  NSHDL has 8 exons (Figure 3) encoding an mRNA of 1581 base pairs, with the first 
methionine codon located at exon 2.  The encoded NSDHL protein is composed of 373 
amino acid residues.  Mutation of the NSHDL leads to abnormalities in the pathway of 
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cholesterol synthesis.  A disruption of the expression of this gene can manifest itself in the 
lack of formation and maintenance of an intact cutaneous barrier, explaining, among other 
sequelae, the ichthyosiform erythroderma that are characteristic for CHILD syndrome (Mi et 
al., 2015).  Loss of function mutations in NSHDL also cause an even more rare congenital 
disease, CK syndrome (Morimoto et al., 2011; Kanungo et al., 2013). 
 
CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM NEVUS AND LIMB 
DEFECTS (CHILD) SYNDROME 
CHILD syndrome is a rare x-linked dominant syndrome, with only 60 cases reported 
worldwide (Souich et al., 2015).  It is a multisystem birth defect that is usually male-lethal, 
with only one documented male case likely due to postzygotic mutation (Happle et al., 1996).  
First described in 1903 by Otto Sachs, symptoms usually present at birth or within the first 
few weeks of development (Bittar and Happle, 2004).  It is usually characterized by an 
inflammatory epidermal nevus with an often wax-like scaling showing a unique lateralization 
pattern (usually on the right side) (Hummel et al., 2003) and a midline demarcation, although 
a single case has been found with symmetrical skin lesions (König et al., 2002).  In addition, 
structural defects may be found ipsilateral to major cutaneous involvement, including hearing 
loss, the shortening or absence of limbs and hypoplasia of the brain, lung, heart, and the 
kidney (Happle et al., 1980; König et al., 2002). It has been hypothesized that the unilateral 
manifestations in CHILD Syndrome could result from interference by mutant cells with a 
small population of organizer cells determining the laterality decision at the midline 
(Hummel et al., 2003). 
Because of the typical clinical and histopathological aspects of the CHILD syndrome 
nevus, a diagnosis can be made in classic cases and also in those cases with only minimal 
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involvement.  CHILD syndrome has been diagnosed in patients with only the ipsilateral 
lesions, with no ipsilateral skeletal defects (Ko et al., 2008).  Female carriers may 
occasionally be found clinically healthy or only having minimal involvement due to X-
inactivation (lyonization) or skewed X-inactivation (McLarren et al., 2010, Yu et al., 2018).   
As a result, numerous sporadic occurrences of CHILD syndrome may be found to be familial 
cases after genetic testing (Bittar et al., 2006). 
Histology of the CHILD syndrome lesions show similar structures as found in VX.  A 
typical epidermal lesion will display acanthosis and marked parakeratosis with lymphocyte 
infiltration involving the upper part of the dermis and a considerable number of neutrophils 
present in the epidermis.  Finally, the dermal papillae contain considerable numbers of foamy 
cells (Happle et al., 1996). These similarities were even seen in a mild case of CHILD 
syndrome. A biopsy from a persistent VX appearing lesion from the left side of the vulva (a 
common location for extraoral VX lesions) of an otherwise asymptomatic 27-year old female 
revealed a broad parakeratotic corneal layer, neutrophil aggregation, and foam cells in the 
dermal papillae.  Molecular analysis confirmed a mutation of the NSDHL consistent with 
those seen in CHILD syndrome (Gantner et al., 2014). 
Mutations in the NSDHL at the Xq28 chromosome locus were identified as the likely 
cause for CHILD syndrome (König et al., 2000).  Soon after, 4 different mutations of the 
NSDHL gene were reported in subjects with CHILD syndrome (Bornholdt et al., 2005), and, 
to date, 20 unique mutations at different exons in the NSDHL gene have been found to cause 
CHILD syndrome (Mi et al., 2015).  While the majority of these mutations have been 
missense or nonsense mutations, cases with frameshift mutations, splice-site mutations, and 
large deletions of multiple exons have also been documented (Bornholdt et al, 2005; Kim et 
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al., 2005; Yu et al., 2018, Yang et al., 2015).  The mutations have also been reported at all 8 
exons in various studies (Mi et al., 2015).  Although there is great variability in the sequelae 
of CHILD syndrome, phenotypic variability does not appear to be associated with a specific 
type or location of the mutations.  The end result of any type of mutation appears to be loss 
of function for the enzyme.  It is believed that a non-functional NSDHL may cause the 
characteristics of CHILD syndrome through the resulting lack of cholesterol, other sterols 
downstream of the block in biosynthesis, or by accumulations of intermediate products 
upstream of the resultant of NSDHL expression (Bornholdt et al., 2005).  Abnormalities in 
cholesterol synthesis would be significant as cholesterol plays a role in the establishment and 
upkeep of a complete cutaneous barrier.  Accumulation of the toxic pathway metabolites 
could also contribute to the characteristic ichthyosis.  In one study, a compounded lovastatin 
and cholesterol topical medication wad designed to treat CHILD syndrome lesions by 
bypassing hepatic first-pass metabolism and allowing access to cutaneous and extracutaneous 
tissues).  This was compared to a purely cholesterol-based control treatment (Paller et al., 
2011).  The treatment with cholesterol alone did not resolve the lesions.  However, the 
addition of the statin appeared to address the toxic metabolites while the supplemental 
cholesterol countered the cholesterol deficiency.  Following 3 months of treatment, the 
previously affected epidermis was of normal thickness, with a regular orthokeratinization and 
normal stratum granulosum (Mi et al., 2015. 
 
CK SYNDROME 
CK Syndrome, named for the initials of an affected patient, is an intellectual 
disability disorder characterized by disparate short height, brain malformations, and 
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dysmorphia (Souich et al., 2009).  Only 24 cases, from 3 unrelated families, have been 
identified, and its prevalence is unknown (Souich et al., 2015).  Like CHILD syndrome, it is 
an x-linked disorder where the primary etiology is dysfunction of the NSDHL gene at the 
Xq28 chromosome.  Unlike the x-linked dominant disease CHILD syndrome, it is inherited 
in a recessive manner, affecting males, and its primary sequelae are mild to severe 
intellectual disability, behavior problems (aggression, attention deficit hyperactivity disorder, 
and irritability), and dysmorphia including amygdaliform eyes, a high nasal bridge, high 
arched palate, long and slender fingers and toes, scoliosis, micrognathia, and a crowded 
dentition (Souich et al., 2009; Morimoto et al., 2012; Kanungo et al., 2013).  The different 
clinical phenotypes may be explained because of the different alleles of the NSDHL gene.  
CHILD syndrome patients have null alleles that result in the complete loss of function of 
NSDHL.  On the other hand, in CK Syndrome, patients possess hypomorphic temperature-
sensitive alleles that result in the partial loss of the functional NSHDL protein (McLarren et 
al., 2010).  The exact process by which this occurs is unclear.  The use of quantitative reverse 
transcriptase PCR, immunoblotting, and immunohistochemistry to determine NSDHL protein 
expression in peripheral tissues identified NSDHL expression in all non-CNS tissues with 
malformations in CK syndrome (and CHILD syndrome) (Morimoto et al., 2012).  Indeed, all 
of these tissues have been shown to synthesize cholesterol.  Furthermore, this established that 
NSHDL gene expression was restricted to specific cells within the tissues.  Autonomous and 
non-autonomous cellular mechanisms could occur because of impairment of the normal 
biological processes by cholesterol deficiency, toxicity of cholesterol biosynthesis 
intermediates or their metabolites.  This may contribute to the particular features of CK 
Syndrome and CHILD syndrome. 
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IMPLICATIONS OF IDENTIFYING THE ROLE OF THE NSDHL GENE IN  
ORAL VERRUCIFORM XANTHOMA 
A previous study was conducted to identify direct associations between CHILD 
syndrome and Verruciform xanthoma (Mehra et al., 2005).  The lesions were perioral or 
extraoral, including the labium, groin, scrotum, thigh, calf, abdomen, and upper lip.  While 
missense mutations that had been reported for CHILD syndrome were not identified, a 
different missense mutation in a common exon (exon 6) of the NSDHL gene was identified 
in 2 out the 7 patients included in the study.  To date, no association between the mutations 
that cause CHILD Syndrome and oral VX lesions has been researched. 
VX cutaneous lesions are associated with CHILD syndrome.  As the syndrome is 
caused by mutations of the NSDHL gene, there is a possibility that oral VX lesions may also 
be associated with a mutation in the NSDHL.  Any mutations noted may help to establish an 
etiologic theory for VX and support further efforts to evaluate risk of NSDHL mutations in 
sterol metabolism disorders like CHILD syndrome or CK syndrome in families with oral VX.
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Figure 1.  Clinical Photographs Submitted with Tissue Biopsies to UNC Oral Pathology 
Laboratory and Biopsy Service.  (A) Test Sample 4.  (B) Test Sample 9. 
 
 
 
 
 
Figure 2.  Histologic Images from Oral Verruciform Xanthoma and Oral Mucocele Lesions 
(H&E Staining).  (A) Test Sample 16 at increasing magnification (xanthoma cell indicated by 
arrow).  (B) Control Sample 1 (oral mucocele). 
 
Figure 1.  Clinical photographs submitted with tissue biopsies to UNC Oral Pathology Laboratory and 
Biopsy Service A. Test Sample 4.  B.  Test Sample 9 
A. B. 
Figure 2.  A.  Test Sample #16 (H&E staining) at increasing magnification (xanthoma cell indicated by arrow).  B.  Control Sample 1 (oral mucocele).  
A. 
B. 
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Figure 3.  NSDHL Gene.  (A) Gene location on the long arm of the X chromosome at 
position 28.  (B) Exons of the NSDHL gene. 
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CHAPTER 2: 
NSDHL MUTATIONS ASSOCIATED WITH CHILD SYNDROME IDENTIFIED IN 
ORAL VERRUCIFORM XANTHOMA
 
INTRODUCTION 
Verruciform xanthoma (VX) is an uncommon benign lesion, commonly 
papillomatous or verruciform, which has an unknown etiology and is seen primarily in the 
oral mucosa (Hegde et al., 2013).  A mutational inactivation of the NAD[P]H steroid 
dehydrogenase-like protein (NSDHL) gene has been reported in cutaneous VX (Mehra et al., 
2015). Lesions resembling VX clinically and morphologically are found in subjects with the 
X-linked dominant lipid storage disease congenital hemidysplasia with ichthyosiform 
erythroderma and limb defects (CHILD) (Mi et al., 2015).  The mutational inactivation of the 
NSDHL gene is a marker for CHILD as well as another lipid storage disease, CK syndrome 
(McLarren et al., 2010).  Between July 2005 and 2017, 112 cases of oral VX were diagnosed 
at the University of North Carolina Oral Pathology Laboratory and Biopsy Service.  We 
proposed to look for a NSDHL gene mutation in diagnosed oral VX cases to begin to 
establish a possible etiological theory for this lesion, and eventually support further efforts to 
evaluate for risk for CHILD or CK syndromes in families with patients with oral VX. 
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MATERIALS AND METHODS 
Archived Samples Collection 
Twenty-five formalin-fixed and paraffin-embedded (FFPE) tissue blocks were 
retrieved from the UNC Oral Pathology Laboratory and Biopsy Service using consecutive 
sampling.  The accession dates ranged from to July 2015 to December 2017.  Twenty of the 
test samples had been previously diagnosed as oral Verruciform xanthoma and five samples 
that had been diagnosed as oral mucoceles served as negative controls.  Each sample came 
from a unique human subject. 
 
DNA Extraction from Samples 
 Five tissue sections (5 µm thick) were produced with a microtome from each selected 
FFPE block.  Each sample was deparaffinized with one 1 mL wash of 100% xylene followed 
by one 1 mL wash in 100% ethanol. The deparaffinized tissues were then subjected to DNA 
extraction using the EX-WAX Paraffin-Embedded DNA Extraction Kit (Millipore Sigma, 
Darmstadt, Germany), according to manufacturer’s instruction.  DNA concentrations and 
260/280 and 260/230 ratios were assessed using a DeNovix DS-11 spectrophotometer 
(DeNovix, Wilmington, DE).  Each DNA sample and its dilution to a 100ng/µL 
concentration (when possible) were stored at -20ºC. 
 
Plasmid Construction 
 A plasmid was designed and subsequently constructed by Invitrogen GeneArt 
Synthesis (Thermo Fisher Scientific, Regensburg, Germany) to include mutations of interest 
previously reported in the literature from Exon 4 and Exon 6 of the NSDHL, including C>T = 
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A105V within Exon 4 and G>C = A182P, G>A = R199H, and G>A = G205S within Exon 6.  
G>A = R199H was associated with a somatic mutation found in Verruciform xanthoma 
tissues and the others have been reported as associated with CHILD Syndrome (Mehra et al., 
2005) (Figures 4, 5).  The plasmid was cloned into the pcDNA3.1_V5-HistA_A122 vector 
and the gene size was 1131 bp.  5µg of the lyophilized DNA was dissolved in 50µL of 
distilled water.  Transformation was accomplished with DH5-alpha competent cells (Thermo 
Fisher Scientific, Durham, NC) according to manufacturer’s instructions.  After overnight 
incubation at 37ºC, the plasmid was recovered using the NucleoSpin Plasmid miniprep kit 
(Macherey-Nagel GmbH & Co., Duren, Germany).  The plasmid and its dilution to a 
75ng/µL concentration were stored at -20ºC.  The plasmid, which would include the 
mutations of interest was constructed for comparison with test samples after spiking into a 
control sample.  This combination would serve as a positive control. 
 
Polymerase Chain Reaction Amplification of Exons 4 and 6 of the NSDHL gene 
 Primer sets were designed to amplify mutations reported in the literature within exons 
4 and 6 of the NSDHL gene (Eton Biosciences, Research Triangle Park, NC) (Mehra et al., 
2005). These include C>T = A105V within Exon 4 and G>C = A182P, G>A = R199H, G>A 
= G205S, and C>T = Q210X within Exon 6.  The primer sequences are 5’-CCA GCT CTG 
AAA GGT GTA AAC ACA-3’ (sense) and 5’-CAA GTT TCA ATG ACA TTC TTG GTG 
CC-3’ (antisense) for exon 4; 5’-A GTT CTG GGC GCC AAC GAT-3’ (sense) and 5’-CAA 
TCA CGA ACT TCA TCT TGC CGT-3’ (antisense) for exon 6.  We later designed an 
additional primer – an intron 5 primer (5’ - GCA CTC TCT TGG CTT GGG – 3’ (sense)) - 
to pair with the previously described exon 6 (antisense) primer to capture an additional 
 23 
mutation described in the literature for CHILD Syndrome, G>C = A182P (Mehra et al., 
2005).  All primer pairs were verified via visualization by electrophoresis on 1.5% agarose 
gels using HEK293T as a DNA template.  The plasmid itself was verified via amplification 
with the exon 4 (sense) and exon 6 (antisense) primer pairs (amplicon size of 409bp).  The 
expected size of polymerase chain reaction (PCR) amplicons with the test and controls 
samples is 119 base pairs for exon 4 sense/antisense primers, 140 base pairs for exon 6 
sense/antisense primers, and 206 base pairs for intron 5 (sense)/exon 6 antisense primers.  
Each amplification was carried out in a Bio-Rad T100 Thermal Cycler (Bio-Rad 
Laboratories, Hercules, CA) in a 50-µL PCR mixture containing:  600ng genomic DNA, 
5µL(50µM) of each sense and antisense primer, 25µl Maxima Hot Start PCR Master Mix 
(2X) (composition: 400µM dATP, 400µM dGTP, 400µM dCTP, 400µM dTTP, 4mM 
magnesium chloride, Maxima Hot Start Taq DNA polymerase in 2X PCR buffer (Thermo 
Fisher Scientific, Durham, NC)), and DNase/RNase-free distilled water.   
The 20 test samples (designated T1-T20) and the 5 negative controls (designated C1-
C5) were amplified with exon 4 primer pairs, the exon 6 primer pairs, and the intron 5/exon 6 
(antisense) primer pairs.  The plasmid was amplified with exon 4 sense and exon 6 antisense 
primers.  As mentioned previously, one of the control samples (C5) spiked with the plasmid 
(C5-PL) and amplified with the same primer pairs served a positive control.  Thermocycling 
conditions used were initial denaturation and hot start at 95°C for 15 minutes, 40 cycles 
consisting of 30 seconds at 95°C, 30 seconds at 60°C, and then 1 minute at 72°C. Following 
thermocycling, reactions were subjected to a 5-minute 72°C incubation. Polymerase chain 
reaction amplicons were visualized by electrophoresis on 2.0% agarose gels and with Gel 
Red (Biotium, Fremont, CA) staining.  After UV transillumination, selected bands 
 24 
corresponding to the aforementioned base pairs length (verified via molecular-weight size 
marker) were incised from the agarose gels for purification. 
 
PCR Purification and Sanger Sequencing of PCR Amplicons 
The agarose gel sections containing the amplified PCR products were purified using 
the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel GmbH & Co., Duren, 
Germany).  DNA was sequenced using a DNA sequencer (model 377; Applied Biosystems, 
Foster City, CA) as previously described (Eton Bioscience, Research Triangle Park, NC).  
The DNA templates used for the sequencing were at the concentration of 10-30ng/µL. 
 
Analysis of Sanger Sequencing 
Reference sequences were obtained from GenBank (NCBI reference sequence 
NM_015922.2) for the human NSDHL cDNA sequence and the mutant NSDHL cDNA 
sequence, which contained the mutations of interest.  Consensus alignments and analysis of 
the sequencing results were completed using Molecular Biology 2.0 software (Benchling, 
San Francisco, CA).  Separate consensus alignments were used for the Exon 4 and Exon 6 
amplicons.  Any mutations were analyzed to determine whether any amino acid change (or 
stop codon) resulted from the base pair change.  Chromatograms were visualized using the 
FinchTV (version 1.5.0) software.  Consensus multiple sequence alignment figures were 
created from relevant chromatograms using the Multalin software 
(http://multalin.toulouse.inra.fr/multalin/). 
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RESULTS 
Successful PCR amplification of the three primer sets was confirmed with PCR 
reactions using HEK293T genomic DNA as a template (Figure 6).  Due to difficulties in 
optimization of the extracted DNA, 16 samples from the original 20 tissue samples were 
selected as test samples for this study (labeled T1-T16).  DNA was successfully extracted 
from all of the original five control samples (C1-C5).  Confirmation that the plasmid 
contained the designed mutations was completed with sequencing of PCR amplicons 
(Figures 7, 8, 9).  The plasmid was successfully spiked into a selected control (C5) tissue 
sample with exon 4 sense and antisense primers (Figure 8) but was unsuccessful with the 
exon 6 sense and antisense primer sets.  
  The mean age of the subjects from whom the oral VX samples were taken was 61.5 
years old with a range of 15-92 years old (Table 1).  The mean age of the control subjects 
was 25 years old with a range of 10-39 years old (Table 2).  In the test group, 68.8% of the 
lesions were found in females (11 out of 16).  In the control group, 3 of the 5 lesions were 
from female subjects (60.0%).  The most common clinical impressions submitted with 
biopsies for the oral VX lesions were dysplasia, papilloma, and squamous cell carcinoma.  
The clinical impressions of the control samples were overwhelming “mucocele.”  This was 
confirmed by the UNC Oral Pathology Laboratory and Biopsy Service.  12 of the 16 test 
samples were listed as coming from the right side of patients (although the side of one of the 
remaining samples was not specified and two were from the patients’ midline, encompassing 
both left and right sides).  Health history information was not available for any of the 
subjects and it is unknown whether any of the subjects had a personal or family history of 
CHILD Syndrome. 
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 Eight of the oral VX lesions (50%) (T1, T2, T4, T8, T9, T14-T16) exhibited a 
mutation in Exon 4 of the NSDHL gene that has been reported for CHILD Syndrome and 
was one of the mutations of interest for this study (Figure 10).  Two of these eight lesions 
had a homozygous missense mutation at c.314 (C>T) at codon 105 (GCG > GTG) that 
results in the replacement of the amino acid alanine by valine at the codon (A105V) in the 
final protein product.  The remaining six lesions had heterozygous missense mutations that 
included the same nucleotide substitution as the homozygous mutations (GCG>GTG) 
(Figures 8, 11).  Neither the A105V mutation nor any other mutation was found in any of the 
remaining 8 oral VX lesions or in any of the 5 control samples (Figure 10). 
Two of the oral VX lesions (12.5%) exhibited two mutations in Exon 6 of the 
NSDHL gene (Figure 12).  One of the mutations has previously been reported for CHILD 
Syndrome and the other was a mutation that was previously reported in the literature 
associated with oral VX (Mehra et al., 2005).  Both of these mutations were mutations of 
interest for this study.  Both T4 and T16 had a heterozygous missense mutation at c.613 
(G>A) at codon 205 (GGC>AGC) that results in the replacement of the amino acid alanine 
by serine at the codon (A205S) in the final protein product (Figure 13).  This mutation was 
one of our mutations of interest and is associated with CHILD Syndrome.  Additionally, each 
of the two lesions had a heterozygous missense mutation at c.596 (G>A) at codon 199 
(CGC>CAC) that results in the replacement of the amino acid arginine by histidine at the 
codon (R199H) in the final protein product (Figure 13).  This mutation was previously 
reported in two oral VX lesions but is not known to be associated with CHILD Syndrome 
(Mehra et al., 2005).  These same two oral VX lesions also had the mutations mentioned 
previously in Exon 4 (see above). Neither the A205V or R199H mutations, nor any other 
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mutation was found in any of the remaining 14 oral VX lesions or in any of the 5 control 
samples (Figure 12).  Additionally, neither of the other mutations of interest (A182P or 
Q201X) was found in these tissue samples or any of the test or control samples (Figure 12). 
A summary of the NSDHL mutational analyses is found in Table 3 and Table 4. 
 
DISCUSSION 
VX lesions are usually found in the oral mucosa, although extraoral locations, 
including, most commonly, the anogenital areas have been reported.  The lesion, regardless 
of the location, has a distinct histopathological pattern of epithelial hyperplasia with 
aggregates of lipid-laden macrophages (often referred to as “foam cells”) in the submucosa 
or papillary dermis.  While other lesions, including oral mucoceles, contain foamy 
macrophages, VX is unique in that the cells are primarily found in the connective tissue.  
Evidence suggests that the characteristic lesions found in CHILD Syndrome, with their 
similar clinical and histological presentation, are strongly related to VX (Xu et al., 2015). 
While the etiology of VX and foamy macrophage accumulation in the connective 
tissue remains unresolved, two prevailing theories have been proposed.  Zegarelli et al 
suggested that epithelial degradation caused by a local irritant initiates formation of the 
characteristic foam cells. The epithelium becomes entrapped with the crypts within the 
stratified squamous epithelium and is not lost from the body.  The entrapped epithelium then 
degenerates, eventually forming lipids.  The products of this breakdown elicit an 
inflammatory response, explaining the neutrophil infiltrate that is often seen within the 
epithelium and a mostly chronic cell infiltrate in the submucosa (Zegarelli et al., 1975).  It is 
unclear, however, how the initial crypts that would necessitate the entrapment of epithelial 
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cells might form.  Additionally, Travis observed foam cell deposition in a multifocal VX in 
the upper aerodigestive tract of a child, in an area of little epithelial degradation.  Noting that 
macrophages are known to produce a variety of growth factors (Nathan, 1987), it was 
suggested that the foam cells might play a role in inducing epithelial hyperplasia.  Therefore, 
the accumulation of foam cells is the primary abnormality in the early lesion, and that 
increasing epithelial hyperplasia and inflammation are secondary (Travis et al., 1989). 
Cholesterol is a major precursor of steroid hormones influencing embryonic and 
postnatal development and is vital to cell membranes.  One of the later steps of its 
biosynthesis involves a 3b-hydroxysteroid dehydrogenase discovered only within the last 15 
years and encoded by the NSHDL gene. The protein is found within the membranes of 
endoplasmic reticulum and on the surface of intracellular lipid storage droplets (Ohashi et al., 
2003).  It has been reported that instead of just being a vessel for lipid storage, the droplets 
themselves may be involved in the regulation of cholesterol biosynthesis.  Normally, if an 
adequate amount of lipid droplets is produced for the local environment, NSHDL migrates 
from the endoplasmic reticulum to the lipid droplets and initiates a negative feedback to stop 
producing lipid droplets.  However, with the introduction of a missense mutation associated 
with CHILD Syndrome (G205S, a mutation detected in our study) into the NSDHL gene, the 
protein was no longer functional and the negative feedback was lost, resulting in an 
increasing level of lipid droplets (Ohashi et al., 2003).  This could account for the foam cells 
that are hallmark for VX lesions. 
Additionally, abnormalities in cholesterol synthesis could prevent the establishment 
and upkeep of a complete cutaneous or epithelial barrier.  It is believed that a non-functional 
NSDHL may cause the characteristic VX lesions of CHILD syndrome either through the 
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resulting lack of cholesterol, other sterols downstream of the block in biosynthesis, or by 
accumulations of intermediate products upstream of the resultant of NSDHL expression 
(Bornholdt et al., 2005). 
Our study was inspired by a previous analysis by Mehra et al. in 2005 that concerned 
the NSDHL gene in cutaneous VX lesions.  The characteristic lesions in cutaneous VX and 
CHILD syndrome have a similar appearance clinically.  When evaluated histologically, they 
both feature foamy macrophages within dermal papilla.  CHILD Syndrome is caused by a 
dysfunction of the NSDHL, caused by a mutation in the NSDHL gene.   Therefore, Mehra et 
al. group was looking for mutations in cutaneous VX lesions that had previously been 
associated with CHILD Syndrome.  To date, there have been over 20 mutations documented 
in the NSHDL gene (Mi et al., 2015).  When their study was conducted over a decade ago, 
they focused on exons 4 and 6, as most of the documented cases involved mutations at these 
locations.  Specifically, they were looking for mutations at codons 105, 182, and 205, which 
resulted in the amino acid changes A105V, A182P, and G205S associated with CHILD 
Syndrome.  They also analyzed for an amino acid change at codon 210, which results in the 
amino acid change Q210X (a stop codon).  While they were unable to find any mutations 
matching those reported for CHILD Syndrome, they did discover a novel missense mutation 
at codon 199 (R199H).  We chose to do a similar study, but now looking for CHILD 
Syndrome mutations in oral VX lesions.  Additionally, we wanted to screen for the presence 
of the somatic mutation that Mehra et al discovered (Mehra et al., 2005). 
Early in the study, we encountered difficulty with successful extraction of the DNA 
from the archived tissue samples.  The tissue samples, derived from oral biopsies, were often 
very small with a high paraffin to tissue ratio, which negatively affected DNA yields.  We 
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eventually had to exclude four tissue samples from the study as the concentration and purity 
of the extracted DNA was poor and amplification with our primer sets was unsuccessful.  We 
also were unsuccessful in generating sequencing results with the amplicon from our exon 6 
primers when spiking the constructed plasmid into a control sample.  This was meant to 
illustrate both the wild type and the mutation simultaneously and serve as positive control.  
This was, however, successful with the exon 4 primer set and it did mirror the heterozygous 
mutation that we discovered with 6 of the test samples. 
In our test samples, eight samples (50%) displayed either a homozygous or 
heterozygous mutation at codon 105 (GCG>GTG), resulting in a replacement of alanine with 
valine in the final protein product (A105V).  Two samples displayed a heterozygous mutation 
at codon 205 (GGC>AGC), resulting in a replacement of alanine by serine in the final protein 
product (G205S).  These two different missense mutations are found in patients diagnosed 
with CHILD Syndrome.  These same two test samples also displayed a heterozygous 
mutation at codon 199 (CGC>CAC), resulting in a replacement of arginine by histidine in the 
final protein product (R199H).  This is the same novel somatic missense mutation 
encountered in the Mehra et al. study.  It is notable that these two test samples are also 
included in the eight test samples that had a mutation at codon 105.  The other mutations of 
interest for our study in exon 6 that had been previously reported with CHILD Syndrome 
(A182P, Q210X) were not found. 
A previous investigation compared the NSDHL gene from humans to similar 
functional genes from other species (Bornholdt et al., 2005).  When compared to other 
functionally similar genes, point mutations present on NSDHL at codon positions 105, 182, 
205, and 210 correspond to areas that are highly conserved and required for protein function 
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(Figure 14).   It is predicted that these genetic mutations influence NAD(P) binding within 
the active site of NSDHL.  While disrupting substrate binding does not necessarily eliminate 
catalytic activity, it will significantly reduce the catalytic efficiency of the enzyme.  Without 
a properly functioning enzyme, metabolism could be disrupted in a cell.  Therefore, it is 
predicted that these newly discovered mutations in the NSDHL gene contribute to a 
reduction in in enzymatic activity of the NSDHL protein, possibly explaining their role in a 
pathologic state. 
Most of the mutations found in this study were heterozygous, while two homozygous 
mutations were found in exon 4 of test samples 1 and 2.  A comparison with known 
mutations in CHILD Syndrome shows similar variability (König et al., 2000, Hummel et al., 
2003, Bittar et al., 2006).  Patients diagnosed with CHILD Syndrome can display a wide 
range of phenotypes ranging from very mild skin lesions to the classic manifestations of the 
syndrome. 
In humans, female cells carry two X-chromosomes and males carry an X and Y 
chromosome.  In the female, one of the X chromosomes is silenced at random with regard to 
parental origin, a process termed X-inactivation, or lyonization.  This randomization occurs 
early in embryonic development and is maintained through all cell divisions.  X-inactivation 
results in every female consisting of a mosaic of two different cell populations (where either 
the paternal or maternal derived X-chromosome is inactivated).  (Deng et al., 2014).  In X-
linked diseases caused by mutation, as is the case with CHILD Syndrome, males are usually 
affected to a significantly greater degree, as they have only one X-chromosome.  In males, 
CHILD Syndrome is overwhelmingly male lethal.  In our study, the only homozygous 
mutations (C>T at codon 105) were found in males.  A more variable phenotype is usually 
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seen in females.  In CHILD Syndrome, heterozygous carriers for the disease can display mild 
symptoms (Yu et al., 2018).  This variability and the common clinical presentation primarily 
on one side of the body (there seems to be a prevalence for the right side (Hummel et al., 
2003) has been explained by mosaicism by lyonization (Hashimoto et al., 1998). 
However, even if an X-linked mutation results in the dysfunction or absence of a 
protein, possibly affecting the growth or potentially causing the death of a particular cell, the 
surrounding environment may provide compensating proteins or signals which may allow 
masking, and function may be restored.  Usually X-inactivation is random, but X-
chromosome inactivation skewing can occur, where the inactivation of one X chromosome is 
favored over the other.  Mouse models have skewing of X inactivation in the NSDHL gene as 
adults (McLarren et al., 2010).  Skewing can be caused by chance or directed by genes.  In 
addition, the selective pressure for skewing does not appear to be the same in all tissues or at 
all developmental stages and skewing can be affected by aging.  Many studies have found 
that skewing is more prevalent in elderly women (Deng et al., 2014). 
While CHILD Syndrome has usually presented as a sporadic manifestation, there are 
eight documented cases of mother to daughter transmission.  In one particular case, the 
proband presented with the spectrum of CHILD Syndrome symptoms, yet her mother and 
grandmother were only affected with a minor scaling lesion on one finger and toe, 
respectively.  Molecular analyses confirmed NSDHL mutations.  The authors concluded that 
the wide range of manifestations might be the result of either extreme lyonization or 
genetically induced skewing of X chromosome inactivation.  Furthermore, they deemed it 
possible that many cases of CHILD Syndrome have not been diagnosed and may have a 
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familial origin (Bittar et al, 2006).  No familial aggregation of Verruciform xanthoma has 
been reported. 
The subjects with our mutations had ages ranging from 15-92 years old (mean age 
61.5 years).  Discounting Test Sample 16 from a 15-year old male patient, our range was 43-
92 years old, with a mean age of 64.6 years.  Furthermore, it is interesting that all of the 
heterozygous mutations that we found in our test samples were derived from female patients, 
except one (the 15-year old male).  Both of the homozygous mutations were found in 67- and 
89-year old men. Comparing our test subjects to CHILD Syndrome patients, male patients 
are extremely rare (only one has been documented). In the reported male patient, he had an 
otherwise normal karyotype, but was heterozygous for “wild-type” and mutant alleles in 
cultured fibroblasts from affected cutaneous lesions.  It has been proposed that the mutation 
represented an early post-zygotic event. 
A final observation was that, as is found with CHILD Syndrome, most of our lesions 
with mutations were found specifically on the right side of the subject (5 out of 8, with two 
of the other 8 samples presenting at the midline, and one from the left side) (Table 1). 
While it is tempting to make direct comparisons between diagnosed CHILD 
Syndrome patients and our oral VX patients, it is important to note that no germline testing 
was conducted for any of the patients from whom we derived tissue samples. 
 
CONCLUSIONS 
We were able to demonstrate that missense mutations found in the NSHDL gene 
known to be associated with CHILD Syndrome can be identified in oral VX lesions through 
DNA sequencing.  Because we only selected specific exons for this study, to mirror a 
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previous study that addressed cutaneous VX lesions, it is possible that additional exons of the 
NSDHL gene may harbor additional identified CHILD Syndrome-associated mutations.  
Additional studies should include sequencing of additional exons of the NSDHL gene.  In 
addition, germline testing of affected patients may be beneficial.  That we were able to 
identify these mutations (and a previously reported somatic mutation unrelated to CHILD 
Syndrome) may contribute to an etiologic theory based on genetics for VX. Further studies 
may contribute to further efforts to evaluate for risk for NSHDL mutation associated 
diseases, including CHILD Syndrome or CK Syndrome in families of subjects with oral VX. 
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Table 1.  Clinicopathologic Characteristics of Test Samples. 
SAMPLE AGE/SEX ANATOMICAL LOCATION CLINICAL IMPRESSION(S) 
T1 67/M Right retromolar pad  Verrucous hyperplasia, papilloma, 
squamous cell carcinoma 
T2 89/M Right mandibular buccal attached 
gingiva (Tooth #30) 
Leukoplakia 
T3 63/F 
Right posterior mandibular buccal 
vestibule 
Verrucous hyperplasia, papilloma, 
squamous cell carcinoma 
T4 92/F Right palatal (Tooth #3) Fibroma 
T5 42/F Right palatal (Tooth #3) Not provided 
T6 70/M 
Right buccal mucosa (Arch 
unspecified) Not provided 
T7 59/F Right palatal (Tooth #3) Papilloma 
T8 76/F Palate (Side unspecified) Irritation fibroma 
T9 81/F Left buccal mucosa (Tooth #19) Epithelial dysplasia 
T10 62/M 
Midline mandibular lingual (Teeth 
#24,25) Verruciform xanthoma 
T11 69/F Right buccal mucosa  Dysplasia, squamous cell carcinoma 
T12 56/F Right lateral of tongue Papilloma 
T13 43/F 
Right (buccal or palatal not 
specified) (Tooth #2) Hyperkeratosis, dysplasia 
T14 45/F 
Right mandibular buccal mucosa 
(Tooth #31)  HPV lesion 
T15 55/F Teeth #24,25 (Buccal/lingual 
gingiva unspecified) 
“Wart” 
T16 15/M Right maxillary buccal papilla 
(Teeth #6/7) 
Not provided 
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Table 2.  Clinicopathologic Characteristics of Control Samples. 
SAMPLE AGE/SEX ANATOMICAL LOCATION CLINICAL IMPRESSION(S) 
C1 28/M Right lower lip  Mucocele 
C2 39/M Right lower lip Mucocele, fibroma 
C3 17/F Lower lip (Side unspecified) Mucocele, fibroma 
C4 31/F Right lower lip Mucocele 
C5 10/F Lower lip (Side unspecified) Mucocele, fibroma 
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Figure 4.  NSDHL Mutations of Interest.  Four known germline mutations associated with 
CHILD Syndrome in Exon 4 and Exon 6 of the NSDHL gene and one somatic mutation 
not known to be associated with CHILD Syndrome in Exon 6 discovered in the 2005 
Mehra Study.  Primer design noted. 
 
 
 
 
 
Figure 5.  Plasmid Engineered with Human HSDHL Mutant Template.  Invitrogen 
GeneArt Synthesis, Germany.  
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Figure 6.  Study Primer Pairs with HEK293T DNA to Confirm PCR Amplification.  
Expected size: 119bp NSDHL Exon 4 F/R; 140bp NSDHL Exon 6 F/R; 206bp NSDHL 
Intron 5F/Exon 6R. 
 
 
 
 
 
 
 
 
 
Figure 7.  Student Exon 4 sense/Exon 6 antisense Primers with Constructed Plasmid.  
Expected size: 409bp. 
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Figure 8.  Sanger Sequencing, Exon 4 Amplicons.  Controls. 
 
 
 
 
                              
        
                     
 
Figure 9.  Sanger Sequencing, Exon 6 Amplicons.  Controls. 
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Figure 10.  Consensus Multiple Sequence Alignment of Exon 4 Sanger Sequencing.  Red 
circles indicate presence of mutation C > T (A105V) in test samples. 
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Figure 11.  Sanger Sequencing, Exon 4 Amplicons.  Test Sample Mutations.  
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Figure 12.  Consensus Multiple Sequence Alignment of Exon 6 Sanger Sequencing.  Red 
circles indicate presence of mutation G > A (R199H) and G > A (G205S) in test samples. 
 
 
 
 
 
 
 
Figure 13.  Sanger Sequencing, Exon 6 Amplicons.  Test Sample Mutations. 
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Figure 14.  Multiple Sequence Alignments Displaying Mutations of Interest in Human 
NSDHL Preferentially Exchange Conserved Amino Acids Across Species.  From the top, 
in order: human, mouse, Saccharomyces cerevisiae, Candida albicans, Macaca mulatta, 
mouse, Mesocricetus auratus.  Identical amino acids are shown in red, mutations observed 
in black, strongly similar amino acids in green, weak similarity is blue.  Black dots 
represent non-conserved positions (Bornholdt et al., 2005).  Also illustrated is the R199H 
mutation from the 2005 Mehra study.  Red circles have been added to denote the 
mutations found in our test samples. 
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